BMS to acquire longtime cell therapy partner 2seventy bio for $286m
The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
What's Your Reaction?
